# of Displayed Technologies: 1 / 1


Targeting β-catenin signaling in combination with EGFR TKI enhances progression free survival and overall survival of EGFR mutant NSCLC
TS-042666 — The discovery of a novel treatment for EGFR TKI drug resistance in NSCLC.
Non-small cell lung cancer (NSCLC), which accounts for 85% of all lung cancers, is one of the leading causes of cancer-related death. Substantial progress has been made in the management of NSCLC as several driver mutations have been identified in cell communication pathways involved in lung tumor…
  • College: College of Medicine (COM)
  • Inventors: Arasada, Rajeswara Rao; Carbone, David
  • Licensing Officer: Davis, Stewart

Loading icon